US Patent

US9700537 — Composition for preventing the occurrence of cardiovascular event in multiple risk patient

Method of Use · Assigned to Mochida Pharmaceutical Co Ltd · Expires 2027-05-31 · 1y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a composition for preventing cardiovascular events in patients with multiple risk factors, including those with high cholesterol.

USPTO Abstract

Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.

Drugs covered by this patent

Vascepa (ICOSAPENT ETHYL) · Amarin Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2707`	—	Vascepa
`U-2707`	—	Vascepa

Patent Metadata

Patent number: US9700537
Jurisdiction: US
Classification: Method of Use
Expires: 2027-05-31
Drug substance claim: No
Drug product claim: No
Assignee: Mochida Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.